ArticleMedical oncology (Northwood, London, England)2025
Combination of SH003 and paclitaxel modulates tumor microenvironment and inhibits metastasis of metastatic melanoma.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Developing therapeutic strategies to overcome immune evasion and resistance posed by the tumor microenvironment (TME) in advanced melanoma remains a significant challenge. This study evaluated therapeutic efficacy of an anticancer herbal extract SH003 combined with Paclitaxel (PTX) in a metastatic melanoma model. Results indicated that the combined therapy of SH003 and PTX not only bolstered antitumor immune responses by reducing influx of regulatory T cells (Tregs) and enhancing infiltration of cytotoxic T cells within the TME, but also significantly curtailed tumor growth and metastasis. Notably, the combined therapy of SH003 and PTX effectively inhibited the EGFR/JAK2/STAT3 and PI3K/AKT/mTOR signaling pathways, which are closely associated with tumor cell survival. Additionally, it reduced the expression of markers associated with metastasis, such as MMP-2, MMP-9, N-cadherin, CXCL9, and CXCL10. These findings suggest that SH003 in combination with PTX can reshape the TME, improve immune cell infiltration, and enhance antitumor immunity, offering a promising strategy to improve therapeutic outcomes of metastatic melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.